ABBVIE Company Profile

✉ Email this page to a colleague

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has one hundred and forty approved drugs.

There are two hundred and forty-three US patents protecting ABBVIE drugs.

There are two thousand nine hundred and seventeen patent family members on ABBVIE drugs in seventy-three countries and four hundred and thirteen supplementary protection certificates in nineteen countries.

Summary for ABBVIE

International Patents:	2917
US Patents:	243
Tradenames:	126
Ingredients:	100
NDAs:	140
Drug Master File Entries:	1
Patent Litigation for ABBVIE:	See patent lawsuits for ABBVIE

Drugs and US Patents for ABBVIE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	LINZESS	linaclotide	CAPSULE;ORAL	202811-002	Aug 30, 2012		RX	Yes	No	8,933,030	⤷ Sign Up	Y			⤷ Sign Up
Abbvie	RINVOQ	upadacitinib	TABLET, EXTENDED RELEASE;ORAL	211675-001	Aug 16, 2019		RX	Yes	No	11,607,411	⤷ Sign Up				⤷ Sign Up
Abbvie	KYBELLA	deoxycholic acid	SOLUTION;SUBCUTANEOUS	206333-001	Apr 29, 2015	AP	RX	Yes	Yes	9,636,349	⤷ Sign Up				⤷ Sign Up
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-003	Apr 11, 2016		RX	Yes	Yes	8,546,399	⤷ Sign Up	Y	Y		⤷ Sign Up
Abbvie	VIEKIRA XR	dasabuvir sodium; ombitasvir; paritaprevir; ritonavir	TABLET, EXTENDED RELEASE;ORAL	208624-001	Jul 22, 2016		DISCN	Yes	No	8,642,538	⤷ Sign Up	Y	Y		⤷ Sign Up
Abbvie	OMNICEF	cefdinir	FOR SUSPENSION;ORAL	050749-001	Dec 4, 1997		DISCN	Yes	No		⤷ Sign Up				⤷ Sign Up
Abbvie	DURYSTA	bimatoprost	IMPLANT;OPHTHALMIC	211911-001	Mar 4, 2020		RX	Yes	Yes	9,492,316	⤷ Sign Up	Y			⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ABBVIE

Subscribe to access the full database, or Sign Up
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-008	Aug 15, 2011	5,631,020	⤷ Sign Up
Abbvie	DEPAKOTE ER	divalproex sodium	TABLET, EXTENDED RELEASE;ORAL	021168-001	Aug 4, 2000	5,212,326*PED	⤷ Sign Up
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	020517-003	Jun 17, 2011	6,036,976	⤷ Sign Up
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-003	Jul 28, 1997	6,676,967	⤷ Sign Up
Abbvie Endocrine Inc	LUPRON DEPOT	leuprolide acetate	INJECTABLE;INJECTION	019732-001	Jan 26, 1989	5,716,640	⤷ Sign Up
Abbvie Endocrine Inc	LUPRON DEPOT-PED KIT	leuprolide acetate	POWDER;INTRAMUSCULAR	020263-005	Jan 21, 1994	5,330,767	⤷ Sign Up
Abbvie	AVYCAZ	avibactam sodium; ceftazidime	POWDER;INTRAVENOUS	206494-001	Feb 25, 2015	8,178,554	⤷ Sign Up
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ABBVIE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	100 mg/25 mg	➤ Subscribe	2008-12-23
➤ Subscribe	Ophthalmic Solution	0.15%	➤ Subscribe	2006-11-03
➤ Subscribe	Extended-release Tablets	1 mg/240 mg	➤ Subscribe	2008-02-20
➤ Subscribe	Capsules	145 mcg and 290 mcg	➤ Subscribe	2016-08-30
➤ Subscribe	Ophthalmic Solution	0.25%	➤ Subscribe	2014-07-30
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2017-06-09
➤ Subscribe	Capsules	100 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Ophthalmic Solution	0.01%	➤ Subscribe	2011-04-05
➤ Subscribe	Delayed-release Capsules	400 mg	➤ Subscribe	2014-06-17
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Capsules	1 mcg and 2 mcg	➤ Subscribe	2008-10-14
➤ Subscribe	Topical Solution	0.03%	➤ Subscribe	2010-05-03
➤ Subscribe	Delayed-release Capsules	135 mg	➤ Subscribe	2009-09-01
➤ Subscribe	Gel	7.5%	➤ Subscribe	2017-02-13
➤ Subscribe	Tablets	400 mg and 600 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Capsules	10 mg and 20 mg	➤ Subscribe	2005-03-30
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-08-16
➤ Subscribe	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	➤ Subscribe	2009-08-04
➤ Subscribe	Tablets	145 mg	➤ Subscribe	2007-10-19
➤ Subscribe	Suppository	1000 mg	➤ Subscribe	2013-05-24
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg	➤ Subscribe	2013-06-17
➤ Subscribe	Injection	400 mg/vial and 600 mg/vial	➤ Subscribe	2014-10-29
➤ Subscribe	Tablets	5 mg/200 mg	➤ Subscribe	2005-05-27
➤ Subscribe	Extended-release Tablet	500 mg	➤ Subscribe	2010-12-06
➤ Subscribe	Capsules	14 mg/10 mg and 28 mg/10 mg	➤ Subscribe	2015-05-18
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-23
➤ Subscribe	Extended-release Tablets	500 mg	➤ Subscribe	2005-02-08
➤ Subscribe	Capsules	7 mg/10 mg	➤ Subscribe	2016-09-26
➤ Subscribe	Ophthalmic Solution	0.10%	➤ Subscribe	2006-12-20
➤ Subscribe	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg	➤ Subscribe	2007-11-09
➤ Subscribe	Oral Solution	80 mg/20 mg per mL	➤ Subscribe	2014-06-19
➤ Subscribe	Ophthalmic Solution	0.2%/0.5%	➤ Subscribe	2008-11-21
➤ Subscribe	Extended-release Tablets	4 mg/ 240 mg	➤ Subscribe	2007-07-24
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2010-12-21
➤ Subscribe	Ophthalmic Solution	0.03%	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	1 mg, 2 mg and 4 mg	➤ Subscribe	2004-10-04
➤ Subscribe	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials	➤ Subscribe	2008-11-28
➤ Subscribe	Ophthalmic Solution	0.5%	➤ Subscribe	2010-12-07
➤ Subscribe	Delayed-release Capsules	45 mg	➤ Subscribe	2009-09-02
➤ Subscribe	Capsules	4 mcg	➤ Subscribe	2008-08-25
➤ Subscribe	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg	➤ Subscribe	2013-01-14
➤ Subscribe	Capsules	5 mg	➤ Subscribe	2005-08-17
➤ Subscribe	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	➤ Subscribe	2017-07-25
➤ Subscribe	Gel	10%	➤ Subscribe	2014-06-19
➤ Subscribe	Tablets	48 mg	➤ Subscribe	2008-07-01
➤ Subscribe	Injection	10 mg/mL (2 mL)	➤ Subscribe	2018-07-13
➤ Subscribe	Extended-release Capsules	28 mg	➤ Subscribe	2013-06-12
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2009-08-12
➤ Subscribe	Tablets	2.5 mg/200 mg	➤ Subscribe	2006-02-24
➤ Subscribe	Delayed-release Tablets	800 mg	➤ Subscribe	2011-07-13
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-06-10
➤ Subscribe	Ophthalmic Solution	0.40%	➤ Subscribe	2005-01-28
➤ Subscribe	Tablets	10 mg, 20 mg, and 40 mg	➤ Subscribe	2015-01-21
➤ Subscribe	Extended-release Tablets	250 mg	➤ Subscribe	2004-05-03
➤ Subscribe	Capsules	21 mg/10 mg	➤ Subscribe	2016-09-23
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-24

International Patents for ABBVIE Drugs

Subscribe to access the full database, or Sign Up
Country	Patent Number	Estimated Expiration
Russian Federation	2333766	⤷ Sign Up
Taiwan	201834656	⤷ Sign Up
Japan	2018123144	⤷ Sign Up
Israel	248466	⤷ Sign Up
Poland	2435432	⤷ Sign Up
South Africa	200903644	⤷ Sign Up
Hong Kong	1083684	⤷ Sign Up
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for ABBVIE Drugs

Subscribe to access the full database, or Sign Up
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2368890	C02368890/01	Switzerland	⤷ Sign Up	FORMER OWNER: ABBVIE BAHAMAS LIMITED, BS
1725537	SPC/GB17/020	United Kingdom	⤷ Sign Up	PRODUCT NAME: ELUXADOLINE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTERED: UK EU/1/16/1126/001-006 20160921
2692346	PA2017033,C2692346	Lithuania	⤷ Sign Up	PRODUCT NAME: PIBRENTASVIRAS ARBA JO FARMACINIU POZIURIU PRIIMTINA DRUSKA; REGISTRATION NO/DATE: EU/1/17/1213 20170726
1499331	SPC/GB13/034	United Kingdom	⤷ Sign Up	PRODUCT NAME: IZINOVA CONCENTRATE FOR ORAL SOLUTION. THE ACTIVE SUBSTANCE IS A MIXTURE OF 3 SALTS:SODIUM SULPHATE ANHYDROUS, MAGNESIUM SULPHATE HEPTAHYDRATE AND POTASSIUM SULPHATE.; REGISTERED: BE BE434323 20130220; UK PL34926/0016 20130313
2203431	2015/009	Ireland	⤷ Sign Up	PRODUCT NAME: DASABUVIR OR A SALT THEREOF, INCLUDING DASABUVIR SODIUM MONOHYDRATE; REGISTRATION NO/DATE: EU/1/14/983 20150115
2618831	SPC/GB17/057	United Kingdom	⤷ Sign Up	PRODUCT NAME: GLECAPREVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT OR ESTER THEREOF; REGISTERED: UK EU/1/17/1213 (NI) 20170728; UK FURTHER MAS ON IPSUM 20170728
2822954	18C1035	France	⤷ Sign Up	PRODUCT NAME: BICTEGRAVIR OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE,EN PARTICULIER BICTEGRAVIR DE SODIUM; REGISTRATION NO/DATE: EU/1/18/1289 20180625
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for ABBVIE

Paragraph IV (Patent) Challenges for ABBVIE drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing